News | May 12, 2023
Gilead acquires XinThera to strengthen pipeline in oncology
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Subscribe To Our Newsletter & Stay Updated